Verastem Inc (VSTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verastem Inc (VSTM) has a cash flow conversion efficiency ratio of -0.878x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.91 Million) by net assets ($49.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Verastem Inc (VSTM) market capitalisation for the company's overall valuation and market capitalisation.
Verastem Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Verastem Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Verastem Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verastem Inc ranked by their cash flow conversion efficiency. Explore Verastem Inc (VSTM) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
0.031x |
|
Khang Dien House Trading and Investment JSC
VN:KDH
|
-0.029x |
|
Velocity Financial Llc
NYSE:VEL
|
0.018x |
|
Shenzhen Lifotronic Technology Co
SHG:688389
|
0.025x |
|
Xiangpiaopiao Food Co Ltd
SHG:603711
|
0.071x |
|
Inly Media Co Ltd
SHG:603598
|
-1.087x |
|
FRoSTA AG
F:NLM
|
0.210x |
|
ACNB Corporation
NASDAQ:ACNB
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Verastem Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Verastem Inc from 2010 to 2025. View Verastem Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.20 Million | $-137.51 Million | -2.404x | -166.30% |
| 2024-12-31 | $-28.89 Million | $-104.77 Million | 3.626x | +340.63% |
| 2023-12-31 | $57.37 Million | $-86.46 Million | -1.507x | -12.16% |
| 2022-12-31 | $47.39 Million | $-63.67 Million | -1.344x | -119.88% |
| 2021-12-31 | $87.56 Million | $-53.50 Million | -0.611x | -110.22% |
| 2020-12-31 | $115.27 Million | $-33.51 Million | -0.291x | +98.49% |
| 2019-12-31 | $7.17 Million | $-138.52 Million | -19.308x | -3120.84% |
| 2018-12-31 | $124.30 Million | $-74.52 Million | -0.599x | +39.66% |
| 2017-12-31 | $57.68 Million | $-57.31 Million | -0.994x | -143.62% |
| 2016-12-31 | $72.30 Million | $-29.48 Million | -0.408x | +8.28% |
| 2015-12-31 | $102.47 Million | $-45.56 Million | -0.445x | -6.95% |
| 2014-12-31 | $88.77 Million | $-36.90 Million | -0.416x | -85.61% |
| 2013-12-31 | $117.45 Million | $-26.30 Million | -0.224x | +10.35% |
| 2012-12-31 | $90.47 Million | $-22.60 Million | -0.250x | -131.48% |
| 2011-12-31 | $-12.77 Million | $-10.13 Million | 0.794x | +878.28% |
| 2010-12-31 | $3.24 Million | $-330.00K | -0.102x | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more